|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular profiling of lung adenocarcinoma. Nature.
511:543–550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Johnson DH, Schiller JH and Bunn PA Jr:
Recent clinical advances in lung cancer management. J Clin Oncol.
32:973–982. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li P, Gao Q, Jiang X, Zhan Z, Yan Q, Li Z
and Huang C: Comparison of clinicopathological features and
prognosis between ALK rearrangements and EGFR mutations in
surgically resected early-stage lung adenocarcinoma. J Cancer.
10:61–71. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Paesmans M: Prognostic and predictive
factors for lung cancer. Breathe. 9:112–121. 2012. View Article : Google Scholar
|
|
7
|
Ke J, Wu R, Chen Y and Abba ML: Inhibitor
of DNA binding proteins: Implications in human cancer progression
and metastasis. Am J Transl Res. 10:3887–3910. 2018.PubMed/NCBI
|
|
8
|
Sikder HA, Devlin MK, Dunlap S, Ryu B and
Alani RM: Id proteins in cell growth and tumorigenesis. Cancer
Cell. 3:525–530. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yokota Y: Id and development. Oncogene.
20:8290–8298. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Antonângelo L, Tuma T, Fabro A, Acencio M,
Terra R, Parra E, Vargas F, Takagaki T and Capelozzi V: Id-1, Id-2,
and Id-3 co-expression correlates with prognosis in stage I and II
lung adenocarcinomapatients treated with surgery and adjuvant
chemotherapy. Exp Biol Med (Maywood). 241:1159–1168. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou XL, Zeng, Ye YH, Sun SM, Lu XF, Liang
WQ, Chen CF and Lin HY: Prognostic values of the inhibitor of
DNA-binding family members in breast cancer. Oncol Rep.
40:1897–1906. 2018.PubMed/NCBI
|
|
12
|
Wen XF, Chen M, Wu Y, Chen MN, Glogowska
A, Klonisch T and Zhang GJ: Inhibitor of DNA binding 2 inhibits
epithelial-mesenchymal transition via upregulation of Notch3 in
breast cancer. Transl Oncol. 11:1259–1270. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin HY, Zeng, Liang YK, Wei XL and Chen
CF: GATA3 and TRPS1 are distinct biomarkers and prognostic factors
in breast cancer: Database mining for GATA family members in
malignancies. Oncotarget. 8:34750–34761. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Thul PJ, Åkesson L, Wiking M, Mahdessian
D, Geladaki A, Ait Blal H, Alm T, Asplund A, Björk L, Breckels LM,
et al: A subcellular map of the human proteome. Science.
356:eaal33212017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Uhlén M, Fagerberg L, Hallström BM,
Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C,
Sjöstedt E, Asplund A, et al: Proteomics. Tissue-based map of the
human proteome. Science. 347:12604192015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nagy A, Lánczky A, Menyhárt O and Győrffy
B: Validation of miRNA prognostic power in hepatocellular carcinoma
using expression data of independent datasets. Sci Rep.
8:115152018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open- label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa
K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al:
First-line crizotinib versus chemotherapy in ALK-positive lung
cancer. N Engl J Med. 371:2167–2177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shaw AT and Solomon BJ: Crizotinib in
ROS1- rearranged non-small-cell lung cancer. N Engl J Med.
372:683–684. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Planchard D, Smit EF, Groen HJM, Mazieres
J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P,
Mookerjee B and Johnson BE: Dabrafenib plus trametinib in patients
with previously untreated BRAFV600E-mutant metastatic
non-small-cell lung cancer: An open-label, phase 2 trial. Lancet
Oncol. 18:1307–1316. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Pembrolizumab versus Chemotherapy for PD-L1-Positive
Non-Small-Cell Lung Cancer. N Engl J Med. 375:1823–1833. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho
BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK,
Bondarenko I, et al: Pembrolizumab versus chemotherapy for
previously untreated, PD-L1-expressing, locally advanced or
metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised,
open-label, controlled, phase 3 trial. Lancet. 393:1819–1830. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gandhi L, Rodríguez-Abreu D, Gadgeel S,
Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ,
Powell SF, et al: Pembrolizumab plus chemotherapy in metastatic
non-small-cell lung cancer. N Engl J Med. 378:2078–2092. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
McAllister SD, Christian RT, Horowitz MP,
Garcia A and Desprez PY: Cannabidiol as a novel inhibitor of Id-1
gene expression in aggressive breast cancer cells. Mol Cancer Ther.
6:2921–2927. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Castañon E, Bosch-Barrera J, López I,
Collado V, Moreno M, López-Picazo JM, Arbea L, Lozano MD, Calvo A
and Gil-Bazo I: Id1 and Id3 co-expression correlates with clinical
outcome in stage III-N2 non-small cell lung cancer patients treated
with definitive chemoradiotherapy. J Transl Med. 11:132013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Martini M, Cenci T, D'Alessandris GQ,
Cesarini V, Cocomazzi A, Ricci-Vitiani L, De Maria R, Pallini R and
Larocca LM: Epigenetic silencing of Id4 identifies a glioblastoma
subgroup with a better prognosis as a consequence of an inhibition
of angiogenesis. Cancer. 119:1004–1012. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Thike AA, Tan PH, Ikeda M and Iqbal J:
Increased ID4 expression, accompanied by mutant p53 accumulation
and loss of BRCA1/2 proteins in triple-negative breast cancer,
adversely affects survival. Histopathology. 68:702–712. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bae WJ, Koo BS, Lee SH, Kim JM, Rho YS,
Lim JY, Moon JH, Cho JH and Lim YC: Inhibitor of DNA binding 2 is a
novel therapeutic target for stemness of head and neck squamouscell
carcinoma. Br J Cancer. 117:1810–1818. 2017. View Article : Google Scholar : PubMed/NCBI
|
